Cells sense and respond to extracellular factors via receptors on the cell surface that trigger intracellular signaling pathways. The signals received by the receptors on hematopoietic cells often determine if the cell proliferates, survives or undergoes apoptosis. Apoptosis can be induced by almost any cytotoxic stimuli. These stimuli may be an absence of signals arising from cellular receptors, stimulation of specific ligand receptors on the cell surface, chemotherapeutic agents, and ionizing radiation or oxygen radicals, as well as a number of other factors. Cellular kinases and phosphatases participate in signaling cascades that influence this process. We review the ability of the calmodulin-dependent-kinases, I-B kinases, PI3-kinases, Jakkinases, PKC, PKA, and MAP kinase signaling pathways (Erk, Jnk, and p38), to influence the apoptotic process. In addition, we discuss the cross-talk that exists between signaling cascades that are pro-apoptotic and anti-apoptotic.
Introduction
Apoptosis is a normal process in which a cell undergoes a series of genetically programmed events that lead to cell death and disposal. The other known mechanism by which cells die is necrosis. Necrosis is not receptor mediated and often occurs due to a lack of nutrients or direct cell trauma. 1 When cells necrose the permeability of the membrane increases causing the cells to swell and eventually burst. The events that occur during necrosis lead to a spilling of the intracellular contents into the extracellular space and a random degradation of the cellular DNA. 1 Necrosis typically leads to an inflammatory response. 1 The events of necrosis are in sharp contrast with those that lead to apoptosis. Following the induction of apoptosis, cells shrink and fragment into membrane-bound vesicles which can be phagocytosed by other cells. 2, 3 A real distinction between these two processes is not clear as many cells when they die have characteristics that are traditionally assigned to one group or the other. 4 The concept that the distinguishing feature of apoptosis is caspase activation has been proposed. 4 The Bcl (B cell leukemia) family of proteins are known regulators of apoptosis. This family consists of proteins that can either enhance or prevent cell death. 5, 6 Depending on the effective levels of the pro-and anti-apoptotic members of this family, cell survival or cell death occurs. In particular, when the effective levels of Bcl-2 or Bcl-X L are high they can heterodimerize with a pro-apoptotic protein known as Bax and prevent apoptosis. 7, 8 When the effective levels of Bcl-2 and Bcl-X L are low, Bax homodimerization is favored which drives the cell toward apoptosis. 7, 8 Bad is a pro-apoptotic Bcl family member which can heterodimerize with anti-apoptotic molecules like Bcl-2. 8 This prevents Bcl-2 or Bcl-X L from heterodimerizing with Bax and renders conditions favorable for Bax homodimerization. When Bax is able to homodimerize it leads to the formation of a transition permeability pore. [9] [10] [11] The formation of this pore results in the release of the contents contained between the inner and outer mitochondrial membrane. The mechanism by which this occurs is unknown; however, it has been postulated that the pore leads to mitochondrial swelling and rupture leading to the release of the contents that are contained between the inner and outer mitochondrial membrane. 12 These contents include cytochrome C and certain caspases. 13 Caspases are proteases that exist in the cell in an inactive state under normal conditions that become activated by proteolysis or cleavage by other proteases. Bcl-X L has also been reported to directly bind to the voltagedependent ion channel (VDAC) protein a constituent of the transition permeability pore. 14 Binding of Bcl-X L to VDAC was demonstrated to inhibit the release of cytochrome c from liposomes. 14 These results suggest that Bcl-X L can also mediate its effects directly at the transition permeability pore.
Caspases can be activated by two distinct mechanisms. 15, 16 Both mechanisms lead to the activation of a similar set of downstream effector caspases. 17 In one case, receptor ligation (eg Fas-or tumor necrosis factor (TNF)-receptor) leads to a high concentration of procaspase 8 brought into the vicinity of the receptor. This in turn results in caspase 8 activation via autocatalytic activity. 17 Caspase 8 activation can then lead to the activation of effector caspases such as caspase 9 and caspase 3. 17 In the other case, procaspase 9 is activated by combining with cytochrome c (released from the mitochondria) and Apaf-1, following certain apoptosis-inducing signals, to form a complex called the apoptosome that cleaves and activates procaspase 3. 12 Bcl-2 has been demonstrated to interact with Apaf-1, 18 however, the functional significance of this interaction is unknown. 19, 20 Caspase 3, once activated, is able to cleave specific cellular proteins. These proteins include PARP, PAK, certain isoforms of PKC, and ICAD. [21] [22] [23] [24] [25] [26] In addition, to the cleavage of specific cellular proteins, nucleic acids are also cleaved into fragments of a specific size during apoptosis. 26 In cells not undergoing apoptosis, phosphatidylserine is contained in the inner leaflet of the cell membrane. However when cells are induced to undergo apoptosis, phosphatidylserine rearranges itself in the membrane and is exposed on the extracellular surfaces of the cell membrane. 27 The aforementioned processes are followed by the formation of apoptotic bodies. Unlike necrosis where the cell swells and bursts, during apoptosis the cell fragments into membrane-bound vesicles. These membrane-bound vesicles have exposed phosphatidylserine on the vesicular membrane and this facilitates uptake of the apoptotic particles by phagocytic cells.
2,3 Unlike necrosis, apoptosis does not generally lead to an inflammatory response. 1, 28 The factors required for apoptosis often pre-exist and do not have to be transcribed or translated following initiation of the signaling pathways that lead to apoptosis. 1 In many cells apoptosis needs to be induced by stimulation of a specific ligand on the cell surface. For example, binding of Fas to the Fas ligand induces apoptosis of the cell expressing the Fas receptor. 22, 29 In contrast, in some cells apoptosis is the default response. For example, many hematopoietic cells require growth factors such as IL-3 or GM-CSF for their survival and if these cells are deprived of growth factors they will undergo apoptosis. 30, 31 Growth factors in addition to inducing proliferation appear to also induce an anti-apoptotic signal. 31, 32 Apoptosis may also be induced by ionizing radiation or oxygen radicals. [33] [34] [35] [36] Induction of apoptosis by oxygen radicals does not require receptor-ligand interactions; however, oxygen radicals and ionizing radiation do induce the activation or inactivation of certain cellular kinases and phosphatases. [37] [38] [39] [40] [41] Clearly, kinases and phosphatases have an important role in the outcome of whether a cell survives, proliferates, differentiates, or undergoes apoptosis.
Apoptosis is an important and beneficial process for the removal of unwanted cells, such as autoreactive T cells. However, there are times when apoptosis can be detrimental to the host. For example, apoptosis is thought to have a major role in the death of T lymphocytes in people infected with HIV. Understanding the pathways involved in inducing, as well as preventing apoptosis has great implications. For example, this knowledge may lead to strategies aimed at preventing some of the loss in T-lymphocyte numbers associated with AIDS. Conversely, understanding the signaling pathways involved in apoptosis may help in identifying therapies to induce apoptosis in malignant cells. This review will focus on the kinases that are involved in the regulation of apoptosis in hematopoietic cells.
The Ras/Raf/Mek/Erk signaling kinase cascade
A number of cellular receptors are known to trigger signaling pathways that result in tyrosine phosphorylation of cellular proteins. 42, 43 One substrate tyrosine phosphorylated in a number of different cell types, including hematopoietic cells and both T-and B-lymphocytes, [44] [45] [46] is a 42-kDa protein. [47] [48] [49] This protein was initially called MAP kinase. This name was based on the ability of this protein to phosphorylate microtubule associated protein. The MAP acronym was also used because this protein was a mitogen activated protein kinase. 50 With the subsequent discovery of additional isoforms of this protein and the discovery of highly related kinases functioning in different kinase cascades, the 42 kDa protein was renamed Erk2 51, 52 and this family of proteins identified by these related activation cascades became known as the MAP kinase family. 53 The MAP kinase family of proteins consists of the Erk (extracellular regulated kinases), Jnk/Sapk (jun N-terminal kinases/stress activated protein kinases), 54, 55 and the p38 kinases. 53, 54 The 42 kDa Erk2 and the 44 kDa Erk1 are the best studied of the MAP kinases. 50 Both Erk1 and 2 are activated by another kinase (Mek; MAP/Erk kinase) that resides immediately upstream of Erk1 and 2. [56] [57] [58] Mek phosphorylates Erk on threonine and tyrosine inducing Erk kinase activity. 59 Once activated the Erk is able to phosphorylate a number of different substrates. These substrates can have activities ranging from phosphotransferase and phosphatase action to the ability to bind other proteins or DNA. 30, 60, 61 There appear to be several pathways that can lead to the activation of the Meks. Both Raf (Raf-1, A-Raf, and B-Raf) and a kinase identified as Mekk (Map or Erk kinase kinase) have been reported to phosphorylate and activate Mek. 44, 45, [62] [63] [64] [65] [66] Ras is capable of activating both Raf [67] [68] [69] and Mekk; 70 however, activation of the Erk pathway can also occur in the absence of Ras activation. 71 The pathways leading to Erk activation are reported to be triggered by receptor tyrosine kinases, 72, 73 The Ras protein is able to signal through a variety of pathways in addition to the Erk signaling pathway.
85-87 For example, activation of Ras leads to the induction of the antiapoptotic kinase PI3-kinase. 88 Evidence that the Erk pathway is involved in preventing apoptosis is derived from experiments using constructs, which encode regulatable forms of Raf and Mek-1. 31, 89, 90 The murine hematopoietic FDC-P1 and human TF-1 cell lines require either IL-3 or GM-CSF for survival and growth. 91 When these cell lines are cultured in media that lacks either of these cytokines they undergo apoptosis. 32, 92, 93 The Raf kinases were demonstrated to prevent apoptosis and promote cytokine independent growth in these cell lines. [30] [31] [32] 90, 94, 95 In these studies FDC-P1 or TF-1 cells were infected with either Raf or Mek-1 retroviral constructs that encoded Raf and Mek chimeric proteins in which the catalytic subunit of these kinases was coupled to the estrogen receptor. The kinase activity of these chimeric proteins was low in the absence of estrogen; however, upon addition of estrogen to these cells the activity of these kinases increases dramatically. When hematopoietic cell lines, infected with these different constructs, were placed in media that did not contain either IL-3 or GM-CSF, clones of cells arose which survived and proliferated in the presence of estrogen. [30] [31] [32] 90, 94, 95 These clones maintained their ability to survive and proliferate in response to stimulation with cytokine as well. In the absence of estrogen or cytokine these Raf infected cells do not proliferate and undergo apoptosis. FDC-P1 and TF-1 cells that were not transfected with the different kinases underwent apoptosis in the presence of estrogen demonstrating that the effects of estrogen were on the regulation of the kinases and not due to an indirect effect of estrogen on these cells. The different Raf constructs (Raf-1, A-Raf, and BRaf) were all capable of preventing apoptosis. [30] [31] [32] 90, 94, 95 However, the ability of these constructs to prevent apoptosis and give rise to growth factor independent cells were quite different from each other. 31, 32, 90 The ability of these constructs was not related to their level of kinase activity toward Mek, although blocking Mek activity did block the ability of the Raftransfected cell lines to survive. 32 One explanation for these seemingly contradictory results is that a certain level of Raf activity is required to rescue these cells from apoptosis and/or for the induction of proliferation, however, too much kinase activity may inhibit these responses. Another explanation is that the actual downstream pathways induced by the three different kinases may differ. Indeed, in a set of experiments using similar Raf constructs, it was reported that high levels 2021 of Raf activity induced the cell cycle inhibitor p21Cip and that there was a differential ability of the three Raf kinases to induce p21Cip. 96 With regards to the ability of activated Raf to block apoptosis, based on the way these experiments were performed, if the conditions were such that proliferation was inhibited and apoptosis prevented, we would have not been able to isolate any clones. Hence, the experiments performed cannot separate the ability of the different forms of Raf to prevent apoptosis from those that prevented apoptosis and induced proliferation when the clones are selected. However, once estrogen responsive clones are isolated, it is clear that removal of the estrogen from these different clones of hematopoietic cells (which contain the different Raf constructs) will induce apoptosis. Thus it is clear under these conditions, that the Raf-1 constructs in addition to being able to induce proliferation of these cells also prevents apoptosis.
Raf-1 is associated with the mitochondria and has been implicated in the phosphorylation of the mitochondrial protein Bad. 97 Phosphorylation of Bad at either serine 112 or serine 133 induces the interaction of BAD with the 14,3,3 protein. 98 Phosphorylated Bad is unable to interact with certain anti-apoptotic Bcl-2 family members shifting the intracellular environment to one favoring cell survival. A-Raf and Raf-1 are the only Raf kinase family members reported to be localized to the mitochondrial membrane. 99, 100 The other family member, B-Raf, also displays anti-apoptotic properties; therefore, it is unlikely that the only mechanism by which the Raf kinases suppress cellular apoptosis is through the phosphorylation of Bad. 90 B-Raf reportedly has anti-apoptotic effects downstream of Bad. The Bcl family of proteins is thought to regulate the release of cytochrome c from the mitochondria. In a series of studies by Erhardt et al, 101 it was demonstrated that B-Raf prevents the activation of the caspases following cytochrome c release. Hence, Raf family members not only effect the release of cytochrome c from the mitochondria but also block the downstream effects once cytochrome c is released.
The ability of the Raf family of kinases to suppress cellular apoptosis also occurs via the aforementioned Erk signaling pathway. All three of the Raf kinases, when activated, will induce increased Mek activity. 90 PD98059 is a pharmacological inhibitor of Mek. When PD98059 was used in these, and similar studies, it blocked the ability of the different Raf constructs to prevent apoptosis. 32, 90 Further evidence for the involvement of the Mek kinases in the prevention of apoptosis was gained by using estrogen-regulated Mek-1 constructs similar to the estrogen-regulated Raf constructs. These constructs also require estrogen to induce kinase activity. When the estrogen-regulated Mek-1 construct was transfected into FDC-P1 cells, apoptosis of these cells was suppressed in the presence, but not absence, of estrogen, 102 demonstrating that activated Mek has anti-apoptotic activity. Similar to the studies that used the Raf constructs, the anti-apoptotic effects of Mek-1 in these studies were also blocked by PD98059. 32, 90, 102 Taken together, these studies demonstrate that not only is the activation of Mek required for Raf-induced prevention of apoptosis in the cells but also that Mek activity by itself is sufficient to block apoptosis in these cells. The involvement of Mek in Raf-induced protection from apoptosis is also supported by the finding that PD98059 also prevents B-Rafmediated suppression of caspase activation 101 and Bad phosphorylation. 98, 103 Hence, it would appear that one of the mechanisms by which activated Raf prevents apoptosis is via the activation of Mek.
Directly downstream of ERK activation is the activation of
Rsk is reported to prevent apoptosis via multiple mechanisms in growth factor dependent cells. p90
Rsk has been shown to phosphorylate the transcription factor CREB. 104 These authors further demonstrated that phosphorylation of CREB promoted cell survival and that preventing phosphorylation of CREB, on the site phosphorylated by p90 Rsk , inhibited cell survival. CREB is also associated with the prevention of apoptosis in melanoma cells, however, the authors of that study were unable to correlate the inhibition of apoptosis with changes in the level of Bcl-2, Bcl-X L , Bad or Bax expression. 105 In addition, p90
Rsk may have anti-apoptotic effects independent of the transcription of anti-apoptotic genes. p90
Rsk has been shown to phosphorylate BAD on serine residue 112. 106, 107 Thus not only are the kinases upstream of Erk involved in the prevention of apoptosis but in addition the kinases downstream of Erk activation appear to play an important role in preventing apoptosis.
Clearly the Ras/Raf/Mek signaling pathway has a large role in the suppression of apoptosis in hematopoietic cells. The multiple roles that the Ras/Raf/Mek signaling pathway has in anti-apoptotic signaling are outlined in Figure 1 . Activated forms of Ras were found to be the strongest inducer of cytokine-independence of these cells. Activated constructs of Raf and Mek could also induce cytokine-independence of these cells with the Raf constructs generally more effective then the Mek. 32, 102 The differences in the ability of the various signaling proteins to prevent apoptosis of these cells is likely due to the spectrum of signaling pathways that each is capable of activating.
The stress-activated protein kinases
The pathways leading to activation of the Jnk (a.k.a. Sapk) and p38 kinases involve a cascade similar to the Erk2 pathway. These pathways are known to be activated by ligation of a variety of receptors such as the TNF or FAS receptor. 108 In addition, the physical environment in which the cell exists may also activate the Jnk and p38 signaling pathways. Both of these pathways can be activated following cellular stress. [109] [110] [111] [112] [113] For example, exposure of cells to ultraviolet light, 114 osmotic 114 or heat shock, 115 and reactive oxygen intermediates 116 have all been shown to trigger either the Jnk or p38 MAP kinase pathways. These same inducers have also been linked to the induction of apoptosis in various cell types. In general, the activation of the Jnk and p38 signaling pathway tends to promote apoptosis whereas the activation of the Erk signaling pathway tends to be anti-apoptotic. 117 In the Jnk pathway, Jnk is phosphorylated and activated by an enzyme known as Jnkk (Figure 1 ). Jnkk is activated by Mekk. 118 Mekk is capable of phosphorylating and activating both Mek and Jnkk; however, it is much more efficient at activating Jnkk. [118] [119] [120] The ability of Ras to activate both Raf and Mekk suggests that it has a role in multiple MAPK pathways. This fact may help explain why in some cases transfection with Ras can also lead to or augment apoptosis. [121] [122] [123] In some cells removal of growth factors results in both Jnk activation and apoptosis. 117 As previously mentioned, removal of IL-3 from the cultures of TF-1 cell leads to the induction of apoptosis in these cells. 124 A very nice series of experiments by Birkenkamp et al 124 demonstrated that IL-3 deprivation of these cells leads to the activation of the Jnk and p38 pathways. IL-3 withdrawal in the presence of an inhibitor of p38 signaling pathway did not result in TF-1 cell apoptosis. 124 To determine if the balance between the Erk and
Figure 1
The role of the MAPK signaling pathways in the prevention and induction of apoptosis. This diagram illustrates the role that the Erk, Jnk, and p38 induced signaling pathways have in apoptosis. The Erk signaling pathway is a kinase cascade that results in the sequential phosphorylation and activation of Raf, Mek, Erk, and p90
Rsk . Once activated both Raf and Mek are able to phosphorylate Bad leading to the inhibition of apoptosis. In addition, B-Raf is proposed to prevent apoptosis downstream of cytochrome c release. The Jnk and p38 pathways tend to promote apoptosis and can be stimulated either via receptors or cellular stress. Cleavage of Mekk by caspase 8 results in a constitutively active form of Mekk.
p38 signaling pathways determines the fate of the cell, Birkenkamp et al 124 incubated cells with IL-1. IL-1 will induce the activation of the Erk, Jnk, and p38 signaling pathways. They found that IL-1, unlike cytokine withdrawal, did not induce apoptosis in these cells. These investigators then demonstrated that inhibition of the Erk signaling pathway with PD98059 allowed IL-1 to induce apoptosis in these cells. These data suggest that although the activation of the p38 pathway may be required for growth factor withdrawal-induced apoptosis, in the presence of high enough levels of Erk activation, p38 activation may not be sufficient in itself for apoptosis to occur. These data also demonstrate that the effects of the Erk signaling pathway can overcome the pro-apoptotic effects of the Jnk and p38 signaling pathways.
TNF is a cytokine that is well known to induce apoptosis. The receptor for TNF is a member of a super family of receptors that also includes FAS. Binding of either of these receptors to their respective ligands results in receptor trimerization and the ability of death domains within the cytoplasmic tail of the receptors to bind various effector molecules. 17 One of the effectors in this system is the FADD protein. FADD recruits and activates caspase 8 leading to the activation of other caspases. 125, 126 One of the targets of the caspases is Mekk-1, which upon cleavage results in a constitutively active form. 127 Cleavage of Mekk-1 results in its activation, as well as the downstream Jnk and p38 kinases. Expression of an activated form of Mekk-1 results in the potentiation of apoptosis to a number of factors including TNF. 128 FAS-induced activation of the Jnk pathway is reported to require caspase activation, 129 however, in the IL-3-dependent cell line BAF-3, over-expression of a Jnk specific phosphatase (M3/6) did not effect FAS-mediated apoptosis. 130 These data support the idea that FAS-induced apoptosis may lead to the induction of Jnk activation, but this activation is not required for FAS-induced apoptosis of hematopoietic cells. In contrast to these findings it was reported, using a dominant-negative Jnk, that Jnk activation is required for apoptosis induced by the Rho family member CDC42. 131 In this study it was demonstrated that Jnk activation resulted in caspase activation. Hence Jnk may be activated by the caspases or it may result in caspase activation. This could result in positive feedback ensuring that once the apoptotic process is initiated, that it is fully completed. In addition, the necessity of Jnk in the apoptotic response is likely to be dependent on the type of apoptotic signal the cell receives.
NF-B
The rel family of transcriptional activators consists of five separate proteins (c-Rel, Rel-b, p50, p52, and p65). The rel family members are homologous proteins that contain a dimerization domain, DNA binding domain and a nuclear localization region. These proteins are capable of forming hetero-and homodimers. When dimerized these proteins are able to bind specific sequences in the DNA and regulate transcription of a number of different genes. 132 The classic form of the NF-B transcription factor is composed of the p65 and p50 rel family members.
133,134 NF-B is inactive when bound to I-B. When NF-B is bound to I-B it is sequestered in the cytoplasm of the cell. 135 However, when I-B is phosphorylated it is targeted for ubiquitination and proteolysis. [136] [137] [138] Once I-B is degraded the nuclear localization site of NF-B is revealed and NF-B can translocate to the nucleus where it is able to act as a transcription factor. 133, 137 The role of NF-B was originally described as a factor that was associated with apoptosis. Many agents, such as TNF-␣ and ligation of the receptor FAS, which induce apoptosis also induced NF-B activation. 139, 140 In addition, it was demonstrated that treatment of cells with pyrrolidine dithiocarbamate, a potent inhibitor of NF-B, prevented etoposideinduced apoptosis in human promyelocytic cells. 141 However it was subsequently shown, using many of these same agents, that inhibition of NF-B potentiated apoptosis. [142] [143] [144] [145] Conversely, inhibition of I-B expression by oligonucleotides was shown to lead to cell transformation. 146 The preponderance of the data now support the concept that NF-B is an antiapoptotic molecule. NF-B localization to the nucleus is reportedly required for the induction of a number of different cytokines and also proteins likely to be involved the prevention of cell death. 147 There is evidence that NF-B has a role in the induction of activation-induced apoptosis of T lymphocytes, however, this is not a direct role and appears to be due to the up-regulation of the FAS ligand on these cells. [148] [149] [150] [151] Blocking NF-B translocation to the nucleus in CD34
+ bone marrow cells prevents bone marrow cell colony formation and leads to the induction of apoptosis of these cells. 152 The cytoprotectant amifostine was reported to inhibit apoptosis in murine myeloid progenitor cells and human cord blood CD34 + cells. It was further reported that amifostine induced NF-B activation and that this activation was required to protect cells from growth factor withdrawal-induced apoptosis. 153 These data suggest a requirement for NF-B in protecting hematopoietic cells from apoptosis under certain conditions. NF-B is clearly associated with oncogenic transformation of hematopoietic cells. Hematopoietic cells do not normally express the c-Mer receptor. However, this tyrosine kinase containing receptor is over-expressed in certain leukemias. Georgescu et al 154 report that expression of a constitutively active form of this receptor leads to cell transformation and prevents growth factor withdrawal-induced apoptosis. When a mutant receptor, in which a tyrosine residue that was important for inducing NF-B activation was mutated, was used in similar studies it was reported that this receptor no longer protected these cells from IL-3 withdrawal. Besancon et al 155 report that transformation of IL-3 dependent BaF/3 cells with TEL/PDGFRbeta prevents cytokine withdrawal-induced apoptosis. These authors also demonstrate that blocking PDGFR tyrosine kinase activity inhibited NF-B activation. Further, they found that preventing NF-B activation in these cells, by either over-expressing a dominant-negative form of I-B or via the inhibition of the proteosome, inhibited the ability of TEL/PDGFRbeta to overcome IL-3 withdrawalinduced apoptosis. 155 Experiments from the laboratory of Albert Baldwin using a super-repressor form of I-B demonstrated that NF-B activation is required for Bcr/Abl induced transformation of primary bone marrow cells. 156 Ras reportedly enhances NF-B activity via Raf-dependent and -independent mechanisms and this is likely to be one of the multiple mechanisms by which Ras can suppress apoptosis. 157 Bcl-X L and a related anti-apoptotic protein known as Bfl-1 are both up-regulated by the transcription factor NF-B.
158-161
Bcl-2 on the other hand is reportedly not under the control of NF-B. 158 Thus it appears that one of the mechanisms by which NF-B may regulate apoptosis is via the up-regulation of these anti-apoptotic proteins.
Since phosphorylation of I-B is critical in the activation of NF-B it makes sense that kinases that lead to the phosphorylation of I-B play a central role in the anti-apoptotic response. A number of factors have been reported to phosphorylate I-B. One of these factors is known as I-kinase. 138 I-kinase is reported to be required for the anti-apoptotic actions of Akt Leukemia (see next section) suggesting one other mechanism by which signaling through the PI3-kinase pathway may help mediate cell survival. 162 I-B is also a downstream target of Mekk1. 132, 134, [163] [164] [165] Hence, Mekk1 appears to mediate signals that are both pro-and anti-apoptotic. It is likely that the balance of many different signals and not any particular signal determines if a cell survives or undergoes apoptosis. Hematopoietic progenitor kinase-1 (HPK-1) has also been reported to phosphorylate and activate I-kinase suggesting that some of the anti-apoptotic properties of this kinase are through the activation of NF-B. Interestingly, HPK-1 is also a target for the caspases and cleavage of HPK-1 changed its biochemical properties. 129 The relationship of the NF-B pathway to apoptosis is summarized in Figure 2 .
Jak/Stat pathway
Triggering of many hematopoietic growth factor receptors leads to the activation of receptor associated proteins known as Jak kinases. 166 Activation of these kinases results in their increased ability to phosphorylate tyrosine residues in the cytoplasmic tail of their respective receptors. This phosphorylation leads to SH2-mediated binding of the Stats to the receptor. Once a Stat is associated with the receptor it is targeted for phosphorylation by the Jak kinases. The phosphorylated Stats disassociate from the receptor, dimerize, and translocate to the nucleus where they are able to act as a transcription factor. 167, 168 Stat signaling is thought to play a significant role in the pathogenesis of some leukemias. 169 Patients suffering from chronic lymphocytic leukemia are reported to contain constitutively phosphorylated Stat protein 170 and constitutive activation of the Jak2/Stat5 pathway is associated with cytokineindependence in hematopoietic cells.
171 Jak2 when fused with Tel results in a constitutively active kinase which confers cytokine-independence to Ba/F3 cells. 172, 173 This may be mediated by autocrine secretion of growth factors as activation of Stat3 results in the autocrine secretion of IL-6. 174 The oncogenes Bcr/Abl and TEL/PDGFR have both been shown to induce the activation of the Stat protein and this may represent one of the mechanisms by which these oncogenes able to induce malignancies. 175, 176 The transcription of Bcl-X L is regulated in part by the Stat proteins. 177 Inhibition of either Stat3 or Stat5 activity results in a down-regulation of Bcl-X L expression. 178, 179 In addition, mutation of the Stat consensus sequence of the Bcl-X L promoter results in decreased Stat5 binding to the site. 180 The activated Stat proteins appear to promote cell survival by multiple mechanisms. The effects of the Stats on transcription of anti-apoptotic genes in some cases are indirect. The Stats are reported to increase the expression of Bcl3 which promotes the formation of the p50 homodimer form of NF-B. 181 The Jak/Stat pathway appears to be very simple at first, however, many complex interactions between this pathway and other signaling pathways occur. For example, the PI3-kinases, Erk kinases and Src kinases are all reported to interact with this pathway. 30 The regulation of this pathway by the MAP kinases appears to be extremely complex as phosphorylation of the Stats appear to be mediated by multiple components of this pathway and serine phosphorylation of the Stats have been reported to both stimulate and inhibit the transcriptional activity of these proteins. [182] [183] [184] [185] To add another level of complexity into this pathway the Jaks have also been reported to activate the Erk kinases. 186 Stancato et al 187 report that IFN-␥ and oncostatin M both activate Raf-1. Both of these cytokines failed to activate Raf-1 in both Jak1 and Stat1, but not Stat2-deficient mice. 187, 188 Stimulation of a number of cytokine receptors (eg IL-4, IL-13, growth hormone, prolactin) result in both the activation of JAKs and the phosphorylation of IRS-1. 189, 190 Phosphorylation of IRS proteins forms docking sites for multiple signaling proteins in anti-apoptotic pathways (eg PI3-K, Grb2). IRS-1 and IRS-2 phosphorylation induced by either growth hormone or prolactin is dependent on Jak2. 189 These results demonstrate potential mechanisms by which the Jak signaling pathway and cytokines can protect cells from apoptosis. Overall, the role of the Jak kinases in apoptosis appears to be anti-apoptotic consistent with the activation of these kinases via cytokine receptors.
PI3-kinase
The anti-apoptotic pathway mediated by PI3-kinase is probably the most studied and best understood pathway in relation to apoptosis. PI3-kinase can influence multiple pathways and mechanisms that are thought to have a role in the apoptotic process. PI3-kinase is an enzyme that is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. Upon binding of the p85 subunit to specific phosphotyrosine residues, the p110 subunit of the enzyme demonstrates enhanced activity towards the 3′ position of the phosphatidylinositol ring. [191] [192] [193] [194] [195] One of these products (PI (3,4,5) P3) is able to induce the activation of two kinases known as PDK1 and PDK2 (phosphatidylinositol-dependent kinase). [196] [197] [198] [199] [200] [201] The PDKs are serine/threonine protein kinases that are thought to phosphorylate Akt on serine 308 (PDK1) and serine 473 (PDK2) contributing to the activation of Akt. [197] [198] [199] [200] [201] In addition, one product of PI3-kinase activation, PI (3,4) P2, is able to directly bind the PH-domain of Akt leading to a 3-5-fold increase in activity. 194, 202 In hematopoietic cells, IL-3 has been reported to activate Akt and a dominant-negative inhibitor of Akt inhibits the ability of these cells to proliferate in response to IL-3. 203 Over-expression of Akt or constitutively active forms of Akt prevent apoptosis due to cytokine withdrawal. 203 Clearly Akt has a role downstream of PI3-kinases in the prevention of apoptosis.
It would appear that some of the anti-apoptotic actions of Akt are mediated at the mitochondria. Activated Akt is capable of leading to the phosphorylation of Bad on serine residue 136 both in vivo and in vitro. 204 Similar to the phosphorylation of Bad on serine residue 112 by Mek, serine phosphorylation of residue 136 is also thought to lead to a decrease in the interaction of Bad with the anti-apoptotic Bcl family members and inhibit the release of cytochrome c from the mitochondria. 205, 206 Akt is also reported to induce the phosphorylation of mitochondrial Raf-1. Dominant-negative Raf-1 inhibits Akt-induced Bad phosphorylation and the ability of Akt to prevent apoptosis. 207 Suprisingly, two reports demonstrated that Akt phosphorylation of Raf inhibited Raf activity. 208, 209 One report suggests that the inhibition of Raf via Akt phosphorylation may be cell type-and stage of differentiation-specific. 208 Hence, Akt probably has both direct and indirect (via Raf-1) effects on Bad phosphorylation.
Hematopoietic cell Bcr-Abl-induced cytokine-independent growth is associated with Bad phosphorylation. Bad phosphorylation mediated by Bcr-Abl requires PI3-kinase activity and could be inhibited, similar to Akt-induced Bad phosphorylation, by a dominant negative form of Raf that was targeted to the mitochondrial membrane. 210 These same investigators, however, found that a sub-population of cells was able to survive even in the absence of Bad phosphorylation suggesting at least two different mechanisms by which apoptosis may be prevented by Bcr-Abl. 210 Akt is also reported to phosphorylate caspase 9 in vitro. This results in the inactivation of caspase 9 and would prevent the activation of effector caspases such as caspase 3 . 211 These data demonstrate that Akt is able to inhibit mitochondria-associated events leading to apoptosis at multiple levels. It is possible that this is the alternative mechanism by which Akt can prevent apoptosis in Bcr-Abl-transformed cells.
Akt has also been reported to phosphorylate and activate the I-kinase. This would result in the phosphorylation and degradation of I-B which in turn leads to the localization of NF-B to the nucleus where it is capable of turning on antiapoptotic genes. 162 Ozes et al 212 have reported that Akt is involved in TNF-␣ induced NF-B activation, however, this report has been disputed. 213 In contrast to NF-B, the forkhead transcription factor induces the transcription of genes that primarily have apoptosis-inducing effects. Brunet et al 214 report that Akt, when activated, will phosphorylate the forkhead protein. This results in the retention of forkhead protein in the cytoplasm where it is unable to induce the transcription of pro-apoptotic genes. The forkhead protein can also modulate cell-cycle progression by increasing the protein levels of p27 kip1 a cell cycle inhibitor. 215 Hence PI3-kinase is able to interact with several apoptotic and anti-apoptotic pathways in the promotion of cell survival. This may be one of the reasons that PI3-kinase has such strong anti-apoptotic properties. The fact that Ras can induce both the PI3-kinase pathway and the Erk pathway may explain why cells are much more efficiently transformed with Ha-Ras than with the estrogen-regulated Raf or Mek constructs.
Insulin-like growth factor (IGF-1) is also reported to prevent apoptosis of some hematopoietic cell lines. [216] [217] [218] In contrast to IL-3 this process is completely reliant on PI3-kinase activity. 217, 218 These authors later determined that IGF-1 induced the up-regulation of Bcl-2 and that IGF-1-induced, but not IL-3-induced, up-regulation of Bcl-2 was PI3-kinase dependent. 192 What is clear is that multiple receptors on the surface of hematopoietic cells may be able to prevent apoptosis via the activation of PI3-kinase.
The ability of these different kinase cascades to independently protect hematopoietic cells from apoptosis was recently demonstrated by Peruzzi et al. 219 In these studies they examined different regions of the IGF-1 receptor and determined the need for these different regions to activate anti-apoptotic signaling pathways. They found that Raf-1 translocation to the mitochondrial membrane, activation of the Erk signaling pathway, and activation of PI3-kinase were all capable of independently blocking apoptosis. All three of these independent antiapoptotic pathways resulted in the phosphorylation of Bad. It is unknown, however, if Bad phosphorylation is required for the anti-apoptotic effects of these signaling pathways. With regards to anti-apoptotic signaling via the IL-3 receptor, both PI3-kinase and activation of the Erk signaling pathway appear to be important. The mechanisms of PI3-kinase in anti-apoptotic signaling are outlined in Figure 3 .
PKA
PKA is a serine/threonine kinase that is activated by cAMP. PKA activation is reported to have both pro-apoptotic and anti-apoptotic effects on hematopoietic cells. Increased cAMP levels have been shown to induce apoptosis in B cells, 220 as well as T cells. [221] [222] [223] Microinjection of cAMP into the myeloid leukemia cell line, IPC-81, induces apoptosis. 224 In addition, Leukemia when PKA is activated by forskolin or analogs of cAMP in primary human CD10 + B cell precursors apoptosis was induced. 225 Very little effect on the levels Bcl-2, Bcl-X L or Bax was noted in these studies following PKA activation, however, activation of PKA did cause the decreased expression of the anti-apoptotic Bcl family member Mcl-1. 225 These studies all suggest a role for PKA activity in the induction of apoptosis. Increases in cAMP are reported to inhibit Ras-dependent Raf-1 activation. [226] [227] [228] PKA is reported to inhibit the activation of Raf by multiple mechanisms. PKA is reported to inhibit the interaction of Raf with Ras 227 and it is reported to inhibit the kinase activity of Raf via PKA-dependent phosphorylation of the Raf kinase domain. 226 It is possible that some of the apoptotic properties of cAMP are mediated via the inhibition of the Ras/Raf/Mek pathway.
A number of studies in hematopoietic cells suggest that PKA activation may also have anti-apoptotic effects. Increases in cAMP and PKA activation have been reported to prevent nitric oxide 229 and ursolic acid 230 induced apoptosis of the human leukemic HL-60 cells. cAMP has also been reported to inhibit apoptosis upstream of caspase 3 activation in human neutrophils. 231 Several studies have shown that PKA activation results in the phosphorylation of Bad on serine residue 112. 232 This is the same site that is phosphorylated by Raf-1 and Mek and may represent the site upstream of caspase 3 activation that is inhibited by PKA. Other studies have demonstrated that PKA may additionally phosphorylate a novel site on Bad. 107 Phosphorylation of this site, serine 155, by PKA also promotes the association of Bad with the 14,3,3 proteins and inhibits Bad's interaction with Bcl-X L . 107 Clearly, increases in cAMP and the subsequent activation of PKA have the potential to inhibit or augment apoptotic responses. The effects of PKA on apoptosis are likely to be largely dependent on the cell type and the mechanism by which apoptosis is induced.
The calmodulin-dependent kinases
One of the earliest known factors shown to induce the apoptosis of cells of the immune system was calcium ionophores. 223, [233] [234] [235] [236] [237] [238] [239] Increases in intracellular calcium that occur following certain apoptosis-inducing signals are not a byproduct of cell death, but appear to be a necessary event in the induction of apoptosis under certain circumstances. 235, 240 Although many factors that induce increases in intracellular calcium will induce apoptosis, and in some cases increases in intracellular calcium alone are sufficient to induce apoptosis, it should be noted that not all agents that induce apoptosis require increases in intracellular calcium. In fact, increases in intracellular calcium have been reported to inhibit apoptosis. Hematopoietic cells cultured in the absence of IL-3 undergo apoptosis, however, increased levels of intracellular calcium protect these cells from apoptosis in the absence of IL-3. [241] [242] [243] Most of the activities of calcium inside the cell are not mediated by free calcium, but rather by calcium bound to calmodulin. One important cellular enzyme that can be activated by increases in intracellular calcium is calcineurin. Calcineurin, or PP2B, is a serine/threonine phosphatase. 244, 245 The immunosuppressive drug cyclosporin A inhibits the activity of calcineurin. 244, 245 Thapsigargin is a compound that increases intracellular calcium by inhibiting the endoplasmic reticular calcium ATPase. When thymocytes are treated with the apoptosis inducing concentrations of thapsigargin, pre- The mechanisms by which activated PI3-kinase is proposed to inhibit apoptosis. This Figure illustrates the multiple points at which PI3-kinase is proposed to have a role in the prevention of apoptosis. PI3-kinase activation results in the activation of the protein kinase Akt. Akt can phosphorylate both Bad and I-K promoting cell survival.
treatment of the cells with cyclosporin A inhibits apoptosis. 246 Cyclosporin A is also capable of blocking apoptosis of HL-60 cells treated with A23187 or thapsigargin. 247 These data suggest a role for calcineurin in the apoptotic process. Calcineurin was shown to dephosphorylate Bad. 248 This would prevent Bad from interacting with the 14,3,3 proteins and allow Bad to translocate to the mitochondria where it can associate with the anti-apoptotic Bcl family members. 248 In some situations, cyclosporin A has the opposite effects. Cyclosporin A has been shown to also prevent apoptosis. Overexpression of p53 in M1 myeloid leukemia cells induces apoptosis that can be inhibited by treating the cells with A23187 or thapsigargin. Treatment of the cells with cyclosporin A prevents A23187 and thapsigargin inhibition of cell death. 249 Thus, similar to calcium the serine/threonine phosphatase, calcineurin can have both pro-and anti-apoptotic effects.
The calmodulin/calcium complex is also capable of activating calcium/calmodulin-dependent-kinase (CaM-K) kinase. CaM-K kinase was reported to activate CaM-K I and IV. [250] [251] [252] CaM-K I is widely expressed and CaM-K IV is expressed primarily in cells of the immune system and neural-and testistissue. 253 The activation of CaM-K kinase can lead to the activation of several pathways that are associated with the prevention of apoptosis. Several reports have demonstrated that increases in intracellular calcium can activate the Erk kinases in a variety of cell types. 46, 82, 254 In Jurkat cells, increases in intracellular calcium lead to CaM-K kinase and CaM-K IV activation. 255 Transfection of Jurkat cells with constitutively active forms of CaM-K IV result in the activation of the Erk signaling pathway. 256 Activation of Erk by increased levels of intracellular calcium has not been demonstrated in IL-3-dependent hematopoietic cells so it is unknown if this is the mechanism by which calcium prevents apoptosis upon growth factor withdrawal.
In a recent article it was demonstrated that CaM-K kinase is able to phosphorylate and activate Akt. 257 Activation of Akt has been shown to lead to the phosphorylation of Bad. 204 At the level of Bad phosphorylation, it would appear that increases in intracellular calcium can drive the response towards apoptosis via calcineurin-mediated dephosphorylation of Bad or it can lead the response toward cell survival via CAM-K kinase-dependent phosphorylation of Bad. It is likely that the balance between these calcium-activated phosphatases and kinases in part determine if the cell is to survive or undergo apoptosis. The multiple roles for the calcium-activated enzymes in the promotion and induction of apoptosis are outlined in Figure 4 .
PKC
The ability of increases in intracellular calcium to induce apoptosis in cells is greatly influenced by the activation of other kinases within the cell. For example, when thymocytes are treated with the calcium ionophore ionomycin, apoptosis ensues, however, when these cells are treated with the combination of both ionomycin and the pharmacologic PKC activator, PMA, the cells do not undergo apoptosis. 258 This suggests a possible role for PKC in anti-apoptotic processes. Stimulation of cells with PMA can have a myriad of effects in addition to the prevention of apoptosis. When FDC-P1 cells are stimulated with PMA, the cells proliferate. [259] [260] [261] However, when TF-1 cells are stimulated with PMA they are induced to differentiate. [262] [263] [264] Growth inhibition mediated by PMA may be mediated in part by p21 WAF1 induction 265 and this occurs in the absence of apoptosis. Thus the direct effects of PMA on apoptosis are hard to interpret.
The general activation of PKC by phorbol esters results in the activation of the Erk signaling pathway in IL-3-dependent cells lines, B-lymphocytes, and T lymphocytes. [44] [45] [46] 254, [266] [267] [268] [269] So it is likely that some of the anti-apoptotic effects of phorbol
Figure 4
The pro-and anti-apoptotic effects of calcium on hematopoietic cells. This Figure illustrates the kinases and phosphatases reported to be involved in the pro-and anti-apoptotic effects of calcium. In the absence of IL-3 calcium is reported to promote cell survival. In the presence of IL-3 calcium can promote apoptosis and this appears to be mediated via calcineurin. Perhaps via the ability of calcineurin to dephosphorylate Bad. CaM-KK, which is activated by the calcium/calmodulin complex, can promote cell survival via the activation of Akt.
esters are mediated via this pathway. However, it appears that other mechanisms exist by which certain isoforms of PKC may prevent apoptosis. One of the classical forms of PKC, PKC-␣, has a potential role in the prevention of apoptosis in hematopoietic cells. Down-regulation of PKC-␣ with anti-sense oligonucleotides leads to apoptosis of U937 cells. 270 PKC-␣ is capable of phosphorylating Bcl-2 at a site which increases its activity so it is likely that this is at least one mechanism by which PKC-␣ inhibits apoptosis. 271 PKC-␣ is clearly not the only factor that can prevent apoptosis in hematopoietic cells. PKC-⑀ is reported to prevent apoptosis in cytokine-deprived TF-1 cells. 272 The mechanism for this may be due to increasing the expression of the Bcl-2 protein. 272 v-Abl inhibits apoptosis of growth factor-dependent hematopoietic cells. 273 The authors of that report suggest that PKC-␤ II may play a role in v-Abl-mediated suppression of apoptosis. 273 Clearly there are multiple forms of PKC involved in the suppression of apoptosis.
Other isoforms of PKC appear to induce apoptosis in hematopoietic cells. PKC-␦, PKC-, and PKC-are targets of caspase 3. [274] [275] [276] Cleavage of these isoforms of PKC results in a catalytic-active fragment which when over-expressed in hematopoietic cells will induce apoptosis. [274] [275] [276] This mechanism may represent a positive feedback loop that ensures that once the apoptotic process is initiated it goes to completion. Thus, depending on the isoform of PKC activated this family of serine/threonine kinases can have a positive or negative effect on cell survival.
Cross talk between apoptotic and anti-apoptotic signaling pathways
A recent report demonstrates that receptors that stimulate apoptotic and anti-apoptotic pathways influence the signaling Leukemia of each other. The laboratory of Keith Kelley found that apoptosis might not occur by solely inducing pathways that lead to apoptosis. Apoptosis may also occur via the ability of some receptors to inhibit signaling by other receptors that are thought to have a role in prevention of apoptosis. 277, 278 These investigators have found using cerebral granular neurons that IGF-1 prevents apoptosis of these cells cultured in low K+ medium. Although TNF is unable to induce apoptosis in these cells alone, it is capable of reversing IGF-1 prevention of apoptosis. 277, 278 The mechanism for this appears to be via inhibition of IGF-1-receptor-induced phosphorylation of IRS-2 and the subsequent inability of this to activate PI3-kinase. 277, 278 These results suggests that with regards to signaling pathways that lead to apoptosis; that inhibition of kinases or activation of phosphatases which signal cell survival may be an important mechanism used by apoptosis inducing signaling pathways. Whether a similar mechanism occurs in hematopoietic cells is not reported.
Benefits of modulation of the apoptotic pathways
There are multiple kinase driven signaling pathways that are likely to contribute to cell survival and cell death in hematopoietic cells. Dysregulated signaling by any of these pathways could contribute to disease. Therefore it is necessary to understand the independent contributions of each of these signaling pathways in inducing malignancies and apoptosis.
One advantage in understanding the pathways that lead to apoptosis or cell survival is the potential benefit of modifying or invoking these cellular pathways in cells that fail to regulate these processes normally. Understanding the mechanisms by which cells become cytokine-independent or by which apoptosis is prevented in certain types of leukemia would aid in the identification of pathways that could serve as potential targets in the treatment of leukemia. With regards to malignant transformation, blocking the activities of the kinases and phosphatases involved in preventing apoptosis could inhibit the growth of these cells. Understanding the signaling pathways that lead to apoptosis will also help identify potential therapeutic targets. In leukemic cells it may be possible to stimulate pro-apoptotic pathways leading to the death of these cells.
